BUZZ-Broker Opinion: Levi's explores new growth avenues beyond its jeans business

路透社2026/10/08 14:14

Show original

October 8 – Levi Strauss (LEVI.N) shares fell about 4% in early trading to $18.79. Boosted by tariff rebates and strong expected demand for high-end jeans and sweaters during the holiday season, the company raised its annual earnings outlook on Wednesday. The median price target among the 16 brokers covering the stock is $26.50, according to data compiled by LSEG. Business diversification is starting to show results. Barclays noted that Levi's expansion beyond jeans is paying off, with tops, women's wear, and emerging lifestyle categories contributing about half of the company’s growth, while it remains the leader in the U.S. jeans market. JPMorgan (rating: "Overweight", price target: $33) believes the slowdown in the direct-to-consumer business is only temporary, mainly due to hot weather in Europe and a misjudgment of U.S. jeans trends, as the business has already started to rebound in this quarter. BTIG (rating: "Buy", price target: $27) said improved demand trends and strong performance in wholesale, international markets, and new categories support a more optimistic outlook for the holiday season and 2027. Needham ("Buy", price target: $28) noted that the temporary weakness in Levi's own stores and website seems to have started to reverse, while growth from tops, women's wear, and other non-jeans categories indicates the brand’s dependence on jeans is declining.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

October 8 - ** Levi Strauss LEVI.N shares fell about 4% in early trading to $18.79

** Boosted by duty drawback and expecting strong demand for its premium jeans and sweaters during the holiday season, the company raised (link) its annual profit outlook on Wednesday

** The median target price from 16 brokerages covering the stock is $26.50—data compiled by LSEG

Diversification efforts are showing results

** Barclays stated that Levi's expansion beyond jeans is delivering results, with tops, womenswear, and emerging lifestyle categories contributing about half of the company’s growth, while it continues to hold a leading position in the US jeans market

** JPMorgan (rating "Overweight", target price: $33) believes the slowdown in the direct-to-consumer business is only temporary, mainly due to hot weather in Europe and a misread of denim trends in the US. Sales in this segment have already started to rebound this quarter

** BTIG (rated "Buy", target price: $27) said that improving demand trends along with strong performance in wholesale, international markets, and new categories supports a more optimistic outlook for the holiday season and 2027

** Needham ("Buy", target price: $28) said that the temporary softness at Levi's own stores and website seems to be reversing, and the growth from tops, womenswear, and other non-denim categories shows that the brand is becoming less dependent on jeans

(To facilitate non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or may not capture the required context, Reuters does not guarantee the accuracy of automated translated texts and provides them solely for reader convenience. Reuters shall not be liable for any damage or loss caused by the use of automated translation features.)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)

路透社•2026/10/08 16:11